AQUIPTA® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.1
THE FIRST ORAL, ONCE-DAILY CGRP RECEPTOR ANTAGONIST DESIGNED SPECIFICALLY FOR THE PREVENTION OF BOTH EPISODIC AND CHRONIC MIGRAINE*1,2
AQUIPTA® has demonstrated inhibitory effects at the CGRP receptor and the amylin-1 receptor, both considered to be involved in migraine pathophysiology.1
CGRP ELEVATED
DURING MIGRAINE3,4
Adapted from Edvinsson L, et al.5 For illustrative purposes only.
AQUIPTA® IS THOUGHT TO INHIBIT
CGRP AT ITS RECEPTORS1
Adapted from Edvinsson L, et al.5 For illustrative purposes only.
The precise mechanism of action of AQUIPTA® in the prevention of migraine remains to be established.1
CGRP, calcitonin gene-related peptide; Ireland.
*In adults who have at least 4 migraine days per month.1
References:
1. AQUIPTA® Summary of Product Characteristics (Ireland). 2. Morena-Ajona D, et al. J Clin Med. 2022;11(6):1656. 3. Rivera-Mancilla E, et al. Expert Opin Drug Saf. 2020;19:1237–1250. 4. Ferrari MD, et al. Nat Rev Dis Primers. 2022;8(1):2. 5. Edvinsson L, et al. Nat Rev Neurol. 2018;14(6):338–350.
WHAT IS THE ROLE OF CGRP IN MIGRAINE?
CGRP is a neuropeptide that has been associated with, and plays an important role in, migraine pathophysiology.1,2
CGRP LEVELS
DURING A MIGRAINE ATTACK
Adapted from Schuster NM, et al.4 and Edvinsson L, et al.5 For illustrative purposes only.
CGRP LEVELS
BETWEEN MIGRAINE ATTACKS
Adapted from Schuster NM, et al.4 and Edvinsson L, et al.5 For illustrative purposes only.
During a migraine attack, serum levels of the neuropeptide increase.2,3
CGRP attaches to its receptors, inducing pain, inflammation and vasodilation.6
References:
CGRP, calcitonin gene-related peptide; Ireland.
1. AQUIPTA® Summary of Product Characteristics (Ireland). 2. Rivera-Mancilla E, et al. Expert Opin Drug Saf. 2020;19:1237–1250. 3. Ferrari MD, et al. Nat Rev Dis Primers. 2022;8(1):2. 4. Schuster NM, et al. Nat Rev Neurol. 2016;12(11):635–650. 5. Edvinsson L, et al. Nat Rev Neurol. 2018;14(6):338–350. 6. Goadsby PJ, et al. Physiol Rev. 2017;97(2):553–622.
IE-AQP-250019 Date of Preparation: October 2025
